BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT

Core Viewpoint - Ascendis Pharma A/S (NASDAQ:ASND) is recognized as one of the best stocks to buy for investment, with a Buy rating reiterated by BofA and a price target set at $246 [1]. Group 1: Analyst Ratings and Price Targets - BofA has maintained a Buy rating on Ascendis Pharma, with a price target of $246 [1]. - Wells Fargo analyst Derek Archila upgraded the price target for Ascendis Pharma from €322 to €330, while keeping an Overweight rating on the stock [2]. - Archila highlighted Ascendis Pharma's operating cash flow guidance of €500 million, excluding TransCon CNP, which suggests a revenue range of €1.1-€1.2 billion for Yorvipath [2]. Group 2: Product Development and Market Potential - The TransCon CNP combined with Skytrofa is expected to potentially become the standard of care over time, indicating significant upside for Ascendis Pharma [3]. - Skytrofa is currently used for treating pediatric growth hormone deficiency, while TransCon is being developed for achondroplasia [3]. - Ascendis Pharma focuses on developing TransCon-based therapies to meet unmet medical needs globally [3].